CTOs on the Move

BioDelivery Sciences International

www.bdsi.com

 
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.bdsi.com
  • 4131 Parklake Avenue Suite 225
    Raleigh, NC USA 27612
  • Phone: 919.582.9050

Executives

Name Title Contact Details
Niraj Vasisht
Senior Vice President and Chief Technology Officer Profile

Funding

BioDelivery Sciences International raised $50M on 05/17/2018

Similar Companies

Johnson & Johnson Vision

Learn about how Johnson & Johnson Vision is committed to addressing the world-wide problems of vision impairment through prevention and treatment.

CPEX Pharmaceuticals

CPEX Pharmaceuticals is a Exeter, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evoke Pharmaceuticals

Evoke Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.

Neurotrope

Neurotrope is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer`s Disease, Fragile X Syndrome and Niemann-Pick Type C